Skip to main content

Table 2 PARP inhibitors in ovarian cancer–G3/G4 Adverse Events

From: Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment

  OLA (%) OLA+CED (%) OLA+CT (%) VEL (%) VEL+CHT (%) NIR (%) RUC (%) INI (%)
Nausea 0–8 5 1 1 0 0 3 0
Vomiting 0–4 0 0 0 0 0.5 0 0
Diarrhoea 0–5 23 0 0 0 0 0 8.3
Dehydration 0 0 0 0 0.4 0 0 0
Hyponatremia 0 0 0 0 0.7 0 0 8.3
Abdominal pain 0–8 0 0 0 0 0 1 0
Headache 0 5 1 0 0 0 0 0
Constipation 0–2 0 0 0 0 0 0 0
Decreased appetite 0–2 0 1 0 0 0.5 0 0
Upper abdominal pain 0 0 0 0 0 0 1 0
Arthralgia 0–1 0 0 0 0 0 0 0
Back pain 0–2 0 0 0 0 0 0 0
Asthenia/fatigue 3–11 27 7 0 0 1.5 6 0
Abdominal distension 0–3 0 0 0 0 0 0 0
Leucopenia 0–2 0 5 0.5 0.7 0 0 0
Neutropenia 0–9 0 43 0.5 0.7 1.5 0 0
Lymphopenia 0–4 0 0 0 4.8 0.5 0 8.3
Thrombocytopenia 0 0 6 0.5 0.4 3.5 0 0
Anemia 0–20 0 9 0 0.7 3 0 0
Hypertension 0 41 0 0 0 0 0 8.3
Peripheral sensory neuropathy 2 0 0 0 0 0 0 0
Drug hypersensitivity 0 0 5 0 0 0 0 0
Dyspnea 4 0 0 0 0 0 0 0
Increased AST 0 0 0 0 0 0 0 8.3
Increased ALT 0 0 0 0 0 0 0 16.7
Increased activated partial thromboplastin time 0 0 0 0 0 0 0 8.3
Hyperbilirubinemia 0 0 0 0 0 0 0 8.3
Increased alkaline phosphatase 0 0 0 0 0 0 0 16.7
Increased international normalized ratio 0 0 0 0 0 0 0 16.7
Malignant pleural effusion 0 0 0 0 0 0 0 8.3
Gastro-oesophageal reflux disease 4 0 0 0 0 0 0 0
Death 0 0 0 0 0 0 0 8.3
  1. OLA Olaparib, VEL veliparib, CED cediranib, RUC rucaparib, NIR niraparib, PLA placebo, unk unknown, mt mutated, wt wild type, Pts patients, NR not reported, P Paclitaxel, CBDC Carboplatin, Res platinum resistant, Ref platinum refractory, CT chemotherapy